The Michael J. Fox Foundation for Parkinson's Research Awards $1.5 Million in Research Grants

Apr 05, 2001, 01:00 ET from The Michael J. Fox Foundation for Parkinson's Research

    NEW YORK, April 5 /PRNewswire/ -- The Michael J. Fox Foundation for
 Parkinson's Research announced today that it has awarded 15 grants totaling
 more than $1.5 million to researchers pursuing a cure for Parkinson's disease.
     Parkinson's disease, a chronic, degenerative neurological disorder that
 affects an estimated 1 million Americans, impairs the central nervous system
 causing difficulty with even the simplest of movements.  Michael J. Fox
 established The Michael J. Fox Foundation for Parkinson's Research in 2000,
 after publicly disclosing in 1998 that he had been diagnosed with the disease
 seven years earlier.
     In keeping with its mission to expedite a cure for Parkinson's, the
 Foundation implemented a rigorous, accelerated grant application review
 process for its initial round of research funding.  The Foundation received
 nearly 200 grant applications from scientists representing 20 countries.
     "This initial round of research grant funding represents an exciting
 first-step in our Foundation's active involvement in the search for a
 Parkinson's cure.  The overwhelming number of proposals that were submitted
 affirm our belief that promising research opportunities exist, merely awaiting
 much-deserved funding," said Michael J. Fox, Founder.  "The Foundation remains
 committed to supporting as much research as possible-and at that end we hope
 to make additional awards within the next few months."
     The Foundation assembled a Grant Review Committee, comprised of 15 highly
 regarded scientists specializing in research areas relevant to Parkinson's
 disease, to conduct its application review process.  "The quality and variety
 of proposals we received was impressive," said J. William Langston, M.D.,
 Scientific Director of The Parkinson's Institute and Chief Scientific Advisor
 to The Michael J. Fox Foundation.  "This first round of grants dramatically
 demonstrates the breadth and depth of innovative research that can be
 encouraged with an efficient and rapid funding process.  I have no doubt that
 the results of these studies will advance our goals of finding the cause, cure
 and better treatments for Parkinson's disease."
 
     Researchers awarded funding by The Michael J. Fox Foundation for
 Parkinson's Research:
 
     Marina E. Emborg, M.D., Ph.D., Rush University, Chicago, IL
     Matthew Goldberg, Ph.D./Jie Shen, Ph.D., Brigham and Women's Hospital at
     Harvard Medical School, Boston, MA
     Stephen Kish, Ph.D., University of Toronto, Toronto, Ontario
     Rudiger Klein, Ph.D., European Molecular Biology Laboratory, Heidelberg,
      Germany
     Ronald J. Mandel, Ph.D., University of Florida College of Medicine,
      Gainesville, FL
     Graeme Mardon, Ph.D., Baylor College of Medicine, Houston, TX
     Eliezer Masliah, M.D., University of California, San Diego, San Diego, CA
     Jose A. Obeso, M.D., Clinica Universitaria de Navarra, Pamplona, Spain
     Amy Rubinstein, Ph.D., Zygogen LLc, Atlanta, GA
     Michael Schwarzschild, M.D., Ph.D., Massachusetts General Hospital,
      Boston, MA
     Lorenz Studer, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY
     Catherine Verfaillie, M.D., Regents of The University of Minnesota,
      Minneapolis, MN
     Gail D. Zeevalk, Ph.D., Robert Wood Johnson School of Medicine,
      Piscataway, NJ
     Renping Zhou, Ph.D., Rutgers University Lab, New Brunswick, NJ
     Michael Zigmond, Ph.D./Ruth G. Perez, Ph.D., University of Pittsburgh,
      Pittsburgh, PA
 
     Research abstracts for these grants as well as biographies for each
 grantee can be viewed on the Foundation's Web site, www.michaeljfox.org.
     The Michael J. Fox Foundation for Parkinson's Research also announces it
 has already begun to work with the NIH and with other private foundations to
 develop plans for a joint funding initiative to support additional research in
 Parkinson's disease.
     "The NINDS congratulates the Michael J. Fox Foundation for Parkinson's
 Research on their efforts to support research that will help us understand how
 Parkinson's disease destroys crucial parts of the brain and develop strategies
 to halt or reverse this degeneration," said Audrey S. Penn, M.D., Acting
 Director of the National Institute of Neurological Disorders and Stroke. "Over
 the next few months, we look forward to working with the Foundation as they
 join others in a larger public-private partnership to leverage our strengths
 in research funding and raise awareness of the needs as well as the exciting
 scientific opportunities in this field."
 
     The Michael J. Fox Foundation for Parkinson's Research is dedicated to the
 fastest possible end to Parkinson's disease.  The Foundation has launched a
 strategic campaign to accelerate, expand and focus funding for the world's
 best research targeting effective treatment and prevention of Parkinson's
 disease.  The Michael J. Fox Foundation pursues every avenue available to
 increase federal funding, as well as support an aggressive fundraising effort
 in both private and corporate arenas to ensure that this critical battle is
 won within the decade.  For more information on The Michael J. Fox Foundation
 for Parkinson's Research, visit http://www.michaeljfox.org .
 
 

SOURCE The Michael J. Fox Foundation for Parkinson's Research
    NEW YORK, April 5 /PRNewswire/ -- The Michael J. Fox Foundation for
 Parkinson's Research announced today that it has awarded 15 grants totaling
 more than $1.5 million to researchers pursuing a cure for Parkinson's disease.
     Parkinson's disease, a chronic, degenerative neurological disorder that
 affects an estimated 1 million Americans, impairs the central nervous system
 causing difficulty with even the simplest of movements.  Michael J. Fox
 established The Michael J. Fox Foundation for Parkinson's Research in 2000,
 after publicly disclosing in 1998 that he had been diagnosed with the disease
 seven years earlier.
     In keeping with its mission to expedite a cure for Parkinson's, the
 Foundation implemented a rigorous, accelerated grant application review
 process for its initial round of research funding.  The Foundation received
 nearly 200 grant applications from scientists representing 20 countries.
     "This initial round of research grant funding represents an exciting
 first-step in our Foundation's active involvement in the search for a
 Parkinson's cure.  The overwhelming number of proposals that were submitted
 affirm our belief that promising research opportunities exist, merely awaiting
 much-deserved funding," said Michael J. Fox, Founder.  "The Foundation remains
 committed to supporting as much research as possible-and at that end we hope
 to make additional awards within the next few months."
     The Foundation assembled a Grant Review Committee, comprised of 15 highly
 regarded scientists specializing in research areas relevant to Parkinson's
 disease, to conduct its application review process.  "The quality and variety
 of proposals we received was impressive," said J. William Langston, M.D.,
 Scientific Director of The Parkinson's Institute and Chief Scientific Advisor
 to The Michael J. Fox Foundation.  "This first round of grants dramatically
 demonstrates the breadth and depth of innovative research that can be
 encouraged with an efficient and rapid funding process.  I have no doubt that
 the results of these studies will advance our goals of finding the cause, cure
 and better treatments for Parkinson's disease."
 
     Researchers awarded funding by The Michael J. Fox Foundation for
 Parkinson's Research:
 
     Marina E. Emborg, M.D., Ph.D., Rush University, Chicago, IL
     Matthew Goldberg, Ph.D./Jie Shen, Ph.D., Brigham and Women's Hospital at
     Harvard Medical School, Boston, MA
     Stephen Kish, Ph.D., University of Toronto, Toronto, Ontario
     Rudiger Klein, Ph.D., European Molecular Biology Laboratory, Heidelberg,
      Germany
     Ronald J. Mandel, Ph.D., University of Florida College of Medicine,
      Gainesville, FL
     Graeme Mardon, Ph.D., Baylor College of Medicine, Houston, TX
     Eliezer Masliah, M.D., University of California, San Diego, San Diego, CA
     Jose A. Obeso, M.D., Clinica Universitaria de Navarra, Pamplona, Spain
     Amy Rubinstein, Ph.D., Zygogen LLc, Atlanta, GA
     Michael Schwarzschild, M.D., Ph.D., Massachusetts General Hospital,
      Boston, MA
     Lorenz Studer, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY
     Catherine Verfaillie, M.D., Regents of The University of Minnesota,
      Minneapolis, MN
     Gail D. Zeevalk, Ph.D., Robert Wood Johnson School of Medicine,
      Piscataway, NJ
     Renping Zhou, Ph.D., Rutgers University Lab, New Brunswick, NJ
     Michael Zigmond, Ph.D./Ruth G. Perez, Ph.D., University of Pittsburgh,
      Pittsburgh, PA
 
     Research abstracts for these grants as well as biographies for each
 grantee can be viewed on the Foundation's Web site, www.michaeljfox.org.
     The Michael J. Fox Foundation for Parkinson's Research also announces it
 has already begun to work with the NIH and with other private foundations to
 develop plans for a joint funding initiative to support additional research in
 Parkinson's disease.
     "The NINDS congratulates the Michael J. Fox Foundation for Parkinson's
 Research on their efforts to support research that will help us understand how
 Parkinson's disease destroys crucial parts of the brain and develop strategies
 to halt or reverse this degeneration," said Audrey S. Penn, M.D., Acting
 Director of the National Institute of Neurological Disorders and Stroke. "Over
 the next few months, we look forward to working with the Foundation as they
 join others in a larger public-private partnership to leverage our strengths
 in research funding and raise awareness of the needs as well as the exciting
 scientific opportunities in this field."
 
     The Michael J. Fox Foundation for Parkinson's Research is dedicated to the
 fastest possible end to Parkinson's disease.  The Foundation has launched a
 strategic campaign to accelerate, expand and focus funding for the world's
 best research targeting effective treatment and prevention of Parkinson's
 disease.  The Michael J. Fox Foundation pursues every avenue available to
 increase federal funding, as well as support an aggressive fundraising effort
 in both private and corporate arenas to ensure that this critical battle is
 won within the decade.  For more information on The Michael J. Fox Foundation
 for Parkinson's Research, visit http://www.michaeljfox.org .
 
 SOURCE  The Michael J. Fox Foundation for Parkinson's Research